BIOMAT Database Logo BIOMAT Database Logo

Immune tolerance in nonhemophilic patients with antibodies to factor VIII. 1988

R W Colman

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

R W Colman
Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients.
June 1981, The Journal of laboratory and clinical medicine,
R W Colman
Acquired factor VIII inhibitors in nonhemophilic patients.
February 1997, Annals of hematology,
R W Colman
Immunosuppression of factor VIII inhibitors in nonhemophilic patients.
April 1993, Seminars in hematology,
R W Colman
Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
April 1988, The New England journal of medicine,
R W Colman
Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
October 2000, Haematologica,
R W Colman
Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.
January 1990, Blood,
R W Colman
Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy.
September 2022, International journal of hematology,
R W Colman
Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction.
January 2024, Pediatric hematology and oncology,
R W Colman
Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.
January 1988, JAMA,
R W Colman
Factor VIII inhibitor treatment. Immune tolerance.
April 1994, Seminars in hematology,
Copied contents to your clipboard!